View Item 

Show simple item record

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

dc.contributor.authorForns, Xavieren_US
dc.contributor.authorCharlton, Michaelen_US
dc.contributor.authorDenning, Jillen_US
dc.contributor.authorMcHutchison, John G.en_US
dc.contributor.authorSymonds, William T.en_US
dc.contributor.authorBrainard, Dianaen_US
dc.contributor.authorBrandt‐sarif, Theoen_US
dc.contributor.authorChang, Paulen_US
dc.contributor.authorKivett, Valerieen_US
dc.contributor.authorCastells, Lluísen_US
dc.contributor.authorPrieto, Martínen_US
dc.contributor.authorFontana, Robert J.en_US
dc.contributor.authorBaumert, Thomas F.en_US
dc.contributor.authorCoilly, Audreyen_US
dc.contributor.authorLondoño, Maria Carlotaen_US
dc.contributor.authorHabersetzer, Françoisen_US
dc.date.accessioned2015-05-04T20:37:23Z
dc.date.available2016-07-05T17:27:59Zen
dc.date.issued2015-05en_US
dc.identifier.citationForns, Xavier; Charlton, Michael; Denning, Jill; McHutchison, John G.; Symonds, William T.; Brainard, Diana; Brandt‐sarif, Theo ; Chang, Paul; Kivett, Valerie; Castells, Lluís ; Prieto, Martín ; Fontana, Robert J.; Baumert, Thomas F.; Coilly, Audrey; Londoño, Maria Carlota ; Habersetzer, François (2015). "Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation." Hepatology 61(5): 1485-1494.en_US
dc.identifier.issn0270-9139en_US
dc.identifier.issn1527-3350en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111285
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherGilead Sciencesen_US
dc.titleSofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111285/1/hep27681.pdf
dc.identifier.doi10.1002/hep.27681en_US
dc.identifier.sourceHepatologyen_US
dc.identifier.citedreferenceCurry MP, Forns X, Chung RT, Terrault NA, Brown R, Jr., Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open‐label study. Gastroenterology 2015; 148: 100 ‐ 107.e1. doi: 10.1053/j.gastro.2014.09.023.en_US
dc.identifier.citedreferenceTerrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531 ‐ 548.en_US
dc.identifier.citedreferenceCrespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373 ‐ 1383.en_US
dc.identifier.citedreferenceWiesner RH, Sorrell M, Villamil F; the International Liver Transplantation Society Panel. Report of the first International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transplant 2003; 9 ( Suppl 3 ): S1 ‐ S9.en_US
dc.identifier.citedreferenceGarcia‐Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680 ‐ 687.en_US
dc.identifier.citedreferenceBerenguer M, Schuppan D. Progression of liver fibrosis in post‐transplant hepatitis C: mechanisms, assessment, and treatment. J Hepatol 2013; 58: 1028 ‐ 1041.en_US
dc.identifier.citedreferenceGane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transplant 2008; 14: S36 ‐ S44.en_US
dc.identifier.citedreferenceBlasco A, Forns X, Carrión JA, García‐Pagán JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492 ‐ 499.en_US
dc.identifier.citedreferenceVerna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS, Jr. Cholestatic hepatitis C following liver transplantation: an outcome‐based histological definition, clinical predictors, and prognosis. Liver Transpl 2013; 19: 78 ‐ 88.en_US
dc.identifier.citedreferenceCharlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long‐term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120 ‐ 1130.en_US
dc.identifier.citedreferenceBerenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus‐related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852 ‐ 858.en_US
dc.identifier.citedreferenceLens S, Gambato M, Londoño MC, Forns X. Interferon‐free regimens in the liver‐transplant setting. Semin Liver Dis 2014; 34: 58 ‐ 71.en_US
dc.identifier.citedreferenceBurton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis 2013; 17: 73 ‐ 91.en_US
dc.identifier.citedreferenceCarrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962 ‐ 970.en_US
dc.identifier.citedreferenceSovaldi (sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences; December 2013. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver‐disease/sovaldi/sovaldi_pi.pdf. Accessed on December 9, 2014.en_US
dc.identifier.citedreferenceLawitz E, Mangia A, Wyles D, Rodriguez‐Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878 ‐ 1887.en_US
dc.identifier.citedreferenceJacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez‐Torres M, Sulkowski MS, et al.; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867 ‐ 1877.en_US
dc.identifier.citedreferenceGordon SC, Towner WJ, Aggarwal AM, Ma J, McNally J, Stamm LM, et al. Integrated safety analysis of sofosbuvir‐based HCV treatment regimens from phase 3 studies. Presented at the 49th Annual Meeting of the European Association for the Study of the Liver, April 9‐13, 2014, London, United Kingdom. Poster 1171.en_US
dc.identifier.citedreferenceCharlton M, Samuel D, Gane E, et al. Sofosbuvir and ribavirin treatment prevents recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015 (in press).en_US
dc.identifier.citedreferenceAmerican Association for the Study of Liver Diseases; the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/. Accessed on December 9, 2014.en_US
dc.identifier.citedreferenceKim B, Trivedi A, Thung SN, Grewal P. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis 2014; 34: 108 ‐ 112.en_US
dc.identifier.citedreferenceDelabaudière C, Lavayssière L, Dörr G, Muscari F, Danjoux M, Sallusto F, et al. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney‐liver transplantation. Transpl Int 2014 Aug 27. doi: 10.1111/tri.12428. [Epub ahead of print].en_US
dc.identifier.citedreferenceFontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601 ‐ 1605.en_US
dc.identifier.citedreferenceChalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al.; Pegasys Transplant Study Group. Peginterferon alfa‐2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289 ‐ 298. Erratum in: H epatology 2005;42:506.en_US
dc.identifier.citedreferenceIssa R, Zhou X, Constandinou CM, Fallowfield J, Millward‐Sadler H, Gaca MD, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross‐linking. Gastroenterology 2004; 126: 1795 ‐ 1808.en_US
dc.identifier.citedreferenceFriedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655 ‐ 1669.en_US
dc.identifier.citedreferenceFontana RJ, Hann HL, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719 ‐ 727.en_US
dc.identifier.citedreferenceOng JP, Younossi ZM, Gramlich T, Goodman Z, Mayes J, Sarbah S, Yen‐Lieberman B. Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001; 71: 1486 ‐ 1487.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hep27681.pdf
Size:
537.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.